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Abstract The mammalian kidney develops from the
ureteric bud and the metanephric mesenchyme. In mice, the
ureteric bud invades the metanephric mesenchyme at day
E10.5 and begins to branch. The tips of the ureteric bud
induce the metanephric mesenchyme to condense and form
the cap mesenchyme. Some cells of this cap mesenchyme
undergo a mesenchymal-to-epithelial transition and dif-
ferentiate into renal vesicles, which further develop into
nephrons. The developing kidney expresses Fibroblast
growth factor (Fgf)1, 7, 8, 9, 10, 12 and 20 and Fgf
receptors Fgfr1 and Fgfr2. Fgf7 and Fgf10, mainly secreted
by the metanephric mesenchyme, bind to Fgfr2b of the
ureteric bud and induce branching. Fgfr1 and Fgfr2c are
required for formation of the metanephric mesenchyme,
however the two receptors can substitute for one another.
Fgf8, secreted by renal vesicles, binds to Fgfr1 and sup-
ports survival of cells in the nascent nephrons. Fgf9 and
Fgf20, expressed in the metanephric mesenchyme, are
necessary to maintain survival of progenitor cells in the
cortical region of the kidney. FgfrL1 is a novel member of
the Fgfr family that lacks the intracellular tyrosine kinase
domain. It is expressed in the ureteric bud and all neph-
rogenic structures. Targeted deletion of FgfrL1 leads to
severe kidney dysgenesis due to the lack of renal vesicles.
FgfrL1 is known to interact mainly with Fgf8. It is there-
fore conceivable that FgfrL1 restricts signaling of Fgf8 to
the precise location of the nascent nephrons. It might also
promote tight adhesion of cells in the condensed meta-
nephric mesenchyme as required for the mesenchymal-to-
epithelial transition.
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Introduction to early kidney development
The metanephric (permanent) kidney of higher vertebrates
is a complex organ comprising thousands of nephrons that
are connected by a branched collecting duct system. The
nephrons represent the functional units of the kidney. They
filter the blood through a basement membrane and drain the
filtrate via tubules and collecting ducts to the bladder.
During embryonic development, the metanephric kidney
develops from two different tissues, both of which are
derived from the intermediate mesoderm, the ureteric bud
and the metanephric mesenchyme [1]. In the mouse,
development of the permanent kidney is initiated at
embryonic day E10.5 when a region of the nephric
(Wolffian) duct near the hindlimbs bulges out and gives
rise to the ureteric bud. The metanephric mesenchyme
sends out signals that induce the ureteric bud to elongate
and to invade the metanephric mesenchyme, where it
subsequently branches in a stereotypical fashion to form
the highly branched collecting duct system. In turn, the
ureteric bud releases signals that induce the metanephric
mesenchyme to condense around the tips of the bud and to
form the cap mesenchyme. Some cells of the cap mesen-
chyme develop into pretubular aggregates that undergo a
mesenchymal-to-epithelial transition and form epithelial
renal vesicles (see Fig. 1). At the stage of the late renal
vesicle, the distal parts of the nascent nephrons fuse with
the ureteric tips to form a contiguous drainage system [2].
Subsequently, the vesicles elongate and form comma-
shaped bodies, which then develop into S-shaped bodies.
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The proximal parts of the S-shaped bodies differentiate into
podocytes and the Bowman’s capsule and eventually
become vascularized, while the more distal parts differ-
entiate into the tubules of the nephron. These tubules
become further segmented into a proximal tubular domain,
the loop of Henle and a distal tubular domain.
Nephron induction and maturation is a continuous pro-
cess that takes place in the cortical region of the developing
kidney. In the mouse, this process continues until about day
P10 after birth and requires nephron progenitor cells that
reside in the peripheral cortical zone of the kidney. The
cortical zone also contains stromal cells that surround and
support the ureteric tips and the nephrogenic mesenchyme
(Fig. 1).
Functional regions of the developing kidney can be
distinguished by the expression pattern of specific marker
genes [1, 3]. The epithelium of the ureteric bud expresses
Wnt9b, Wnt11 and Ret. Nephrogenic precursor cells in the
cortical region of the developing kidney express Cited1,
whereas stromal precursor cells express Foxd1. The unin-
duced metanephric mesenchyme expresses, amongst other
marker genes, Gdnf, Six1, Eya1, Six2, Sall1, Pax2 and
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Fig. 1 Schematic drawing of
early kidney development.
Nephron formation takes place
in the cortical region of the
developing kidney. Reciprocal
signaling between the tips of the
ureteric bud and the
metanephric mesenchyme leads
to branching of the ureteric tips
and to condensation of the
mesenchyme around these tips.
Some cells of the condensed
mesenchyme form pretubular
aggregates that undergo a
mesenchymal-to-epithelial
transition (MET) into renal
vesicles. Subsequently, the
vesicles form comma-shaped
bodies that further develop into
S-shaped bodies. The proximal
parts of the S-shaped bodies
differentiate to glomeruli, while
the distal parts differentiate to
tubules. Some of the marker
genes that are specifically
expressed in ureteric buds,
stroma, cap mesenchyme,
pretubular aggregates and renal
vesicles, respectively, are
indicated. The adult mouse
kidney comprises
approximately 12,000 nephrons
2506 B. Trueb et al.
123
Wt1. Results obtained with knockout mice suggest a pre-
cise molecular hierarchy, in which one factor acts upstream
of the other to induce a molecular signaling cascade:
Eya1 [ Six1 [ Six2 [ Sall1 [ Pax2. Finally, renal vesi-
cles express Pax8, Fgf8, Wnt4 and Lhx1 (Fig. 1).
Nephron development is a tightly controlled process that
is regulated by various growth factors and morphogens.
These proteins act in different signaling pathways,
including the Fgf/Fgfr, the Wnt/b-catenin and the Notch/
Presenilin pathway. To initiate nephron formation, Wnt9b
is secreted from the ureteric bud into the metanephric
mesenchyme where it activates the canonical b-catenin
pathway [4]. In response, the metanephric mesenchyme
secretes Fgf8 [5, 6] and Wnt4 [7]. Fgf8 is required for cell
maintenance and survival during different stages of neph-
rogenesis (see also below). Wnt4 induces cells from the cap
mesenchyme to undergo the mesenchymal-to-epithelial
transition, which finally leads to the formation of renal
vesicles. Signaling by Notch and Presenilin is subsequently
required to pattern the tubules of the nascent nephrons
[8, 9].
The Fgf/Fgfr signaling system
The Fgf/Fgfr signaling pathway will be described here in
more detail because it involves FgfrL1, the major topic of
this review. The Fgf/Fgfr system comprises a diverse pal-
ette of ligands, receptors, coreceptors and modulating
proteins. Humans and mice possess 22 different Fgfs that
can be grouped according to sequence and specificity in 7
distinct subfamilies [10]: the Fgf1 subfamily (Fgfs 1, 2),
the Fgf4 subfamily (Fgfs 4, 5, 6), the Fgf7 subfamily (Fgfs
3, 7, 10, 22), the Fgf8 subfamily (Fgfs 8, 17, 18), the Fgf9
subfamily (Fgfs 9, 16, 20), the endocrine Fgf subfamily
(Fgfs 15/19, 21, 23; Fgf19 is the human orthologue of
mouse Fgf15), and the subfamily of Fgf homologous fac-
tors (Fgfs 11, 12, 13, 14). Fgf homologous factors appear to
serve an unrelated, intracellular function and will not be
considered further here. All Fgfs are monomeric proteins
that interact with heparan sulfate proteoglycans, which act
as coreceptors and increase their activity. Together with the
heparan sulfate, they bind to four different receptors
(Fgfr1–Fgfr4), induce their dimerization and trigger
downstream signaling events [11]. A ternary complex
consisting of two Fgfrs, two Fgf ligands and two heparan
sulfate chains appears to be the active complex at the cell
membrane. Once activated, the receptors signal by various
pathways to the interior of the cells, including the MAPK
pathway, the PI3K/Akt pathway, the Jak/Stat pathway and
the PLCc pathway [12].
All Fgfrs display the same overall structure [11]. They
contain a signal peptide that is cleaved off after synthesis,
three extracellular immunoglobulin (Ig)-like domains D1–
D3, a single transmembrane domain and a split intracellular
tyrosine kinase domain (Fig. 2). The first Ig-domain is
separated from the second by a stretch of acidic residues
that has been termed the ‘‘acidic box’’. In the case of Fgfr1,
the best-studied Fgf receptor, the intracellular domain
contains seven tyrosine residues that become phosphory-
lated after ligand binding in a sequential and precisely
ordered fashion (Y-653, Y-583, Y-463, Y-766, Y-585,
Y-654, Y-730) [13]. Phosphorylation leads to binding of
adapter proteins, such as Frs2 and Shc, and to downstream
signaling, in the case of the MAPK pathway via the Frs2/
Grb2/Sos/Ras/Raf/Mek/Erk cascade. Moreover, tyrosine
residue Y-766 is a docking site for PLCc. Binding of PLCc
to the receptor leads to activation of the phospholipase and
to cleavage of phosphatidylinositol into diacylglycerol and
inositol triphosphate, both of which act as second messen-
gers. Several proteins have been identified that modulate
Fgf signaling at different levels. Positive regulation is
mediated by anosmin and Flrt3, while negative regulation is
mediated by Dusp and several Spry/Spred proteins.
A further level of regulation is achieved by alternative
splicing of the mRNA precursors for the Fgfs and Fgfrs
[11]. In the case of the receptors, the third Ig domain D3 is
subject to alternative splicing. In the genes for Fgfr1, Fgfr2
and Fgr3, this domain is encoded by three exons, exons
IIIa, IIIb and IIIc. All isoforms contain exon IIIa, but exons
IIIb and IIIc are spliced in a mutually exclusive manner to
generate two different splice variants, the b- and the
c-variant. No similar alternative exon is found in the Fgfr4
gene. Thus, the four different receptor genes can be tran-
scribed and translated into seven different receptor
proteins, Fgfr1b, Fgfr1c, Fgfr2b, Fgfr2c, Fgfr3b, Fgfr3c
and Fgfr4. The b-variants are usually expressed in epithe-
lial tissues, whereas the c-variants are mainly found in
mesenchymal tissues. The Fgf ligands bind to a pocket of
the receptor that is formed by Ig domains D2 and D3.
Alternative splicing of the D3 domain, as observed in the
b- and c-variants, will therefore affect the ligand binding
properties of the receptors.
FgfrL1, the fifth Fgf receptor
A decade ago, we discovered a fifth Fgfr and termed it
FgfrL1 (fibroblast growth factor receptor-like 1) [14, 15].
This receptor is found in most multicellular animals from
Cnidarians to vertebrates [15, 16]. Similar to the classical
receptors, it contains a signal peptide and three extracel-
lular Ig-like domains, the first being separated from the
second by a stretch of hydrophilic residues comparable to
the ‘‘acidic box’’ of the other receptors (Fig. 2). The
extracellular part shares about 40 % sequence similarity
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with receptors Fgfr1–Fgfr4. However, the intracellular
domain of FgfrL1 is considerably shorter than those of the
other receptors and does not share much similarity with any
other protein. This region also reveals very low sequence
conservation among different animal species with the
exception of a stretch of 20 residues at the very C-terminal
end. This end comprises 6–10 dipeptide repeats, where His
residues alternate with Thr or Ser residues. We found that
this His-rich region binds zinc ions [17] and interacts with
proteins of the Spry/Spred family [18]. Preceding the His-
rich region, there are two conserved tyrosine motifs that
appear to act as sorting signals. These motifs target the
receptor to the late endosomes and lysosomes and are
therefore involved in the turnover of FgfrL1 [19].
The mode of action of FgfrL1 is not yet known. FgfrL1
binds to Fgf ligands, with relatively high affinity to Fgfs 3,
4, 8, 10 and 22 and with somewhat weaker affinity to Fgfs
2, 5, 17, 18 and 23 [20]. However, it does not appear to
bind to Fgf1, 6, 7, 9, 12, 16, 18, 19, 20 and 21. FgfrL1 also
interacts with heparin and heparan sulfate containing pro-
teoglycans [21, 22]. The interacting proteins on the surface
of HEK293 cells have been identified as glypican-4 and
glypican-6 [23]. While binding to ligands and heparin
appear to follow the common scheme of the classical
receptors, signaling does not. FgfrL1 does not contain any
protein tyrosine kinase activity at its intracellular domain
and consequently cannot signal by trans-autopho-
sphorylation. Therefore it has been suggested that FgfrL1
might act as a decoy receptor, which sequesters Fgf ligands
away from the signaling receptors [20, 24]. Such a decoy
activity is particularly likely for the receptor after shed-
ding. We have demonstrated that a certain percentage of
FgfrL1 is shed from the cell surface by an as yet uniden-
tified protease [20]. Shedding of FgfrL1 appears to be
minimal in HEK293 and COS-1 cells, but nearly complete
in C2C12 cells when these cells differentiate into myotu-
bes. The shed receptor appears to bind and neutralize some
Fgf ligands in the extracellular space. Another possibility
includes that FgfrL1 might dimerize with the classical
receptors and block transphosphorylation at the intracel-
lular domain. However, this possibility does not seem
likely because FgfrL1 forms constitutive homodimers at
the plasma membrane as demonstrated by FRET mea-
surements and co-precipitation studies [22]. A third
possibility would be that it accelerates the turnover of the
classical receptors. To do so, FgfrL1 would have to interact
in some way with the conventional Fgfrs, but so far there is
no evidence for such an interaction. Yet a fourth possibility
would be that FgfrL1 recruits signaling molecules, such as
inhibitors and tyrosine phosphatases, to the sites where the
other receptors are expressed. The interaction of FgfrL1
with members of the Spry/Spred family might point into
this direction [18]. We have found that FgfrL1 recruits
Spred1 to the plasma membrane via its His-rich domain.
Spred/Spry proteins are known as negative regulators of
tyrosine kinase receptors. In fact, a negative effect on cell
proliferation was observed when FgfrL1 constructs were
transfected into MG63 cells [21]. Furthermore, FgfrL1
blocked Fgf signaling when its mRNA was injected into
Xenopus oocytes [20].
The most astonishing function of FgfrL1, however, is its
effect on cell–cell fusion. We observed that FgfrL1 accu-
mulated at sites of cell–cell contact [22]. When coated on
plastic surfaces, it promoted adhesion of various cell types,
including HEK293, 3T3 and CHO. Furthermore, when
over-expressed in CHO cells, it induced fusion of these
cells into large syncytia comprising several hundred nuclei
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Fig. 2 Domain structure of the Fgf receptors and comparison with
FgfrL1. All proteins have an extracellular part with three Ig-like
domains (D1–D3), the first being separated from the second by a
linker comprising many hydrophilic residues. This linker has been
termed ‘‘acidic box’’ in the case of the classical receptors. Each Ig-
like domain is stabilized by a disulfide bond (‘‘C–C’’). Fgfr1–Fgfr4
contain a split tyrosine kinase domain in their intracellular part.
FgfrL1 is lacking this kinase domain but instead contains a histidine-
rich region that interacts with zinc ions. Fgfr1 harbors seven tyrosine
residues (indicated by ‘‘Y’’) that become phosphorylated after ligand
binding. These residues are fully conserved in Fgfr2, but only
partially conserved in Fgfr3 and Fgfr4. FgfrL1 contains two tyrosine
residues in its intracellular domain that are involved in sorting of the
receptor to the late endosomes and lysosomes. There is no evidence
that these residues become phosphorylated in FgfrL1
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[23]. FgfrL1 was also able to fuse heterologous cells, such
as HeLa, MG63, COS7, C2C12, with CHO cells. For the
fusogenic activity, only the third Ig domain and the
transmembrane domain were required. The other domains
(D1, D2, intracellular domain) were not needed and
appeared to modulate or even repress the fusogenic activ-
ity. It is worth mentioning in this context that the D3
domain of the classical receptors Fgfr1–Fgfr4 do not
exhibit any cell fusion activity [23].
Cell–cell fusion plays a fundamental role during
embryonic development of most animals [25, 26]. It is
observed during fertilization when sperm and egg fuse,
later in the formation of bones when macrophages fuse to
osteoclasts, then in skeletal muscle when myoblasts fuse to
myotubes and finally in the placenta where the trophoblasts
fuse to the trophoblast layer. While the fusion of viruses
with the host plasma membrane has been studied in detail,
fusion of entire cells to syncytia is poorly understood.
Nevertheless, it has been demonstrated that ‘‘fusogens’’,
proteins that actively merge the two cell membranes, play a
decisive role. To date only a few fusogens have been
described, such as EFF-1 and AFF-1 from C. elegans and
Duf, Rst, Sns and Hbs from Drosophila. Interestingly, EFF-1,
AFF-1, Duf, Rst, Sns and Hbs are all members of the
Ig-domain superfamily, suggesting that Ig-domains are
involved in the fusion process [25, 26]. FgfrL1 is the first
mammalian protein that has been shown to trigger cell–cell
fusion in vitro.
Fgfs in early kidney development
Initial RT-PCR studies demonstrated that most Fgfs are
expressed in the developing rat kidney (Fgfs 1, 2, 3, 4, 5, 7,
8, 9, 10) [27]. A recent analysis of the mouse transcriptome
provided by the GUDMAP database showed expression of
Fgfs 1, 7, 8, 9, 10, 12 and 20 in the nephrogenic zone of
developing kidneys [28]. Among these, Fgf1, 7, 10 and 20
are expressed primarily in the cap mesenchyme, Fgf8 in the
renal vesicle, Fgf9 in the cap mesenchyme as well as the
ureteric epithelium and Fgf12 only in the ureteric bud
(Fig. 3).
Early reports demonstrated that some Fgfs have pro-
found effects on growth and differentiation of cells and
tissues derived from metanephric mesenchyme and ureteric
bud. When ureteric bud cells were cultivated in vitro, they
secreted several soluble factors that stimulated growth of
uninduced mesenchymal tissue and prevented apoptosis.
One of these factors was identified as Fgf2 (basic Fgf) [29].
When added to mesenchymal tissues cultivated in vitro,
Fgf2 promoted mesenchymal condensation, although it did
not induce conversion of the mesenchyme to epithelial
structures [30]. In cooperation with other soluble factors
(TGFb, LIF), however, it was able to convert kidney
mesenchyme into tubules [31, 32].
When tested on isolated ureteric buds cultivated in vitro,
several factors, including Fgf1, Fgf2, Fgf7 and Fgf10, were
found to have a positive effect on proliferation and
branching morphogenesis [33]. Fgf7, if overexpressed in
hepatocytes of transgenic mice, induced morphological
abnormalities of several organs [34]. The most striking
aberrations were hyperplasia and cystic dilation of the
collecting duct system in the kidney, suggesting that tight
regulation of Fgf7 expression is critical for normal kidney
development.
Inactivation studies performed with knockout mice
demonstrated altered renal phenotypes for Fgf7, Fgf8,
Fgf9, Fgf10 and Fgf20 deficient mice (Table 1). In con-
trast, deletion of Fgf1, Fgf2 or compound deletion of Fgf1
and Fgf2 resulted in viable, fertile mice that displayed very
mild phenotypes and no renal defects [35]. Targeted dis-
ruption of Fgf7 and Fgf10, ligands known to bind to
Fgfr2b, led to defects in the collecting duct system. Fgf7
null mice were viable and did not show severe abnormal-
ities, although the animal’s fur exhibited a matted
appearance due to a defect in the hair shaft [36]. Mor-
phometric analyses of kidneys from such Fgf7 deficient
mice revealed that the collecting duct system was smaller
than that of control mice. Adult mice had 30 % fewer
nephrons than wild-type mice [37].
Fgf10 knockout mice were generated in two different
laboratories [38, 39]. Fgf10 null mice lacked all limbs and
died at birth due to complete absence of the lungs,
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Fig. 3 Schematic diagram of a ureteric tip with locations of Fgf and
Fgfr expression. A branching ureteric tip surrounded by cap
mesenchyme is depicted. Some cells of the cap mesenchyme have
aggregated and undergone a transition to epithelial renal vesicles.
Expression of Fgf ligands and Fgf receptors is indicated in specific
compartments. Differences in the expression levels between Fgfr1
and Fgfr2 are indicated by the relative size of the fonts
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demonstrating a role for Fgf10 in lung and limb morpho-
genesis. Similar to Fgf7, knockout of Fgf10 resulted in
smaller kidneys with fewer renal tubules and collecting
ducts compared to wild-type mice [40]. These defects
resemble the phenotype of Fgfr2b deficient mice (see
below), suggesting that Fgf10 acts as the major ligand for
Fgfr2b.
Recently, Michos et al. [41] found that Fgf10 is needed
for branching of the ureteric bud in mice that lack Gdnf/Ret
and Spry. In the absence of the negative regulator Spry,
Gdnf/Ret signaling is no longer required for extensive
kidney development. In this case, the removal of only one
copy of the Fgf10 gene caused a complete failure of ureter
and kidney development. The authors speculated that Gdnf/
Ret signaling is the major trigger for growth of the ureteric
tips and that in its absence, Fgf10/Fgfr2b signaling might
be able to substitute to a large extent [41].
Fgf8 is essential for gastrulation [42]. Consequently, a
conditional knockout strategy had to be used to study the
effects of Fgf8 on kidney development. Two different
groups generated conditional Fgf8 knockout mice. Gries-
hammer et al. [5] used the Pax3 promoter to drive
expression of Cre recombinase in the metanephric mesen-
chyme and to delete a floxed Fgf8 allele. Perantoni et al.
[6] used the Brachyury T promoter to drive Cre recombi-
nase in all mesodermal cells and to delete a floxed Fgf8
allele. Both groups found that mutant offspring died shortly
after birth and displayed abnormally small kidneys. Fgf8 is
Table 1 Effects of targeted
disruption of Fgf ligand and Fgf
receptor genes on early kidney
development in the mouse
ko knockout, UB ureteric bud,
MM metanephric mesenchyme
Gene Targeting strategy
(promoter of cre)
Effect relative to wild-type kidney Ref.
Fgf ligands
Fgf1-/- General ko Normal kidneys [35]
Fgf2-/- General ko Normal kidneys [35]
Fgf1-/-; Fgf2-/- Compound deletion Normal kidneys [35]
Fgf7-/- General ko Mild, smaller kidneys, fewer ureteric tips [37]
Fgf10-/- General ko Smaller kidneys, fewer ureteric tips
(lung agenesis)
[40]
Fgf8MM-/- Conditional ko in MM
(Pax3)
Renal hypoplasia, arrest at renal vesicle
stage
[5]
Fgf8MM-/- Conditional ko in
mesoderm (T)
Renal hypoplasia, arrest at renal vesicle
stage
[6]
Fgf9-/- General ko Normal kidneys (malformations of lung
and testis)
[45]
Fgf20-/- General ko Reduced kidney size [46]
Fgf9-/-; Fgf20-/- Compound deletion Kidney agenesis [43]
Fgf9-/-; Fgf20?/- Compound deletion Normal kidneys [43]
Fgf9?/-; Fgf20-/- Compound deletion Hypoplastic kidneys (15–60 % reduced size) [43]
Fgf receptors
Fgfr2b-/- General ko Smaller kidneys with fewer nephrons
(lung agenesis)
[51]
Fgfr1UB-/- Conditional ko in UB
(Hoxb7)
Normal [56]
Fgfr2UB-/- Conditional ko in UB
(Hoxb7)
Smaller kidneys, aberrant branching,
fewer nephrons
[56]
Fgfr1MM-/- Conditional ko in MM
(Pax3)
Normal [60]
Fgfr2MM-/- Conditional ko in MM
(Pax3)
Normal, sometimes two ureteric buds [61]
Fgfr1MM-/-; Fgfr2MM-/- Conditional ko in MM
(Pax3)
Kidney aplasia, little MM,
unbranched UB
[60]
Fgfr1MM-/-; Fgfr2c-/- Conditional ko in MM
(Pax3)
Similar to Fgfr1MM-/-; Fgfr2MM-/-
but more MM
[62]
Fgfr3-/- General ko Normal kidneys [53]
Fgfr4-/- General ko Normal kidneys [54]
Fgfr3-/-; Fgfr4-/- Compound deletion Normal kidneys [54]
FgfrL1-/- (Fgfr5-/-) General ko Severe renal dysgenesis/agenesis [64]
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usually expressed in pretubular aggregates, renal vesicles,
comma- and S-shaped bodies, but not in the ureteric bud or
the interstitial stroma (Fig. 3). Kidneys of Fgf8 mutant
mice still contained some renal vesicles but these did not
progress to the stage of the comma- and S-shaped bodies.
The mutant kidneys also showed reduced branching of the
ureteric bud. Cell death occurred at significantly increased
rate in regions where the mesenchymal-to-epithelial tran-
sition takes place in wildtype animals as well as in the
cortical zone where nephrogenic precursor cells reside.
Expression of Wnt4 and Lhx1 was absent, an observation
that explains the failure of the mutant kidneys to convert
the metanephric mesenchyme into nephron epithelia. Res-
cue experiments proved that Fgf8 as well as Wnt4 were
required to sustain Lhx1 expression and tubule formation.
Fgf8 is therefore required to maintain survival of cells in
S-shaped bodies and to support survival of progenitor cells
in the peripheral zone of the developing kidney [5, 6].
The roles of Fgf9 and Fgf20 in kidney formation were
recently described [43]. The authors demonstrated that
these growth factors are necessary and sufficient to main-
tain progenitor stemness in the cortical zone of the kidney.
The adult kidney does not possess any stem cells for
renewal but relies on a surplus of nephrons generated
during development from an embryonic pool of progenitor
cells. These progenitor cells are located distal to the ure-
teric bud in the cap mesenchyme and express Six2 and
Sall1.
Global disruption of the Fgf9 gene resulted in mice that
died at birth due to severe lung hypoplasia [44]. The Fgf9
deficient mice showed aberrant development of the male
reproductive tract, but the kidneys developed normally
[45]. The Fgf20 gene was targeted by insertion of a
b-Galactosidase cDNA into the first exon [46]. Fgf20 null
mice were viable and fertile, although they suffered from
hearing loss and showed slight reduction in the size of the
kidney. It was only when the researchers generated com-
pound mutant animals that they found severe alterations in
the kidney [43]. Compound null embryos (Fgf9-/-;
Fgf20-/-) showed complete kidney agenesis. In contrast,
compound heterozygous animals (Fgf9?/-; Fgf20?/-) did
not display any overt abnormalities. Animals lacking both
alleles of Fgf20 and one allele of Fgf9 (Fgf9?/-; Fgf20-/-)
exhibited hypoplastic kidneys with defects ranging from
mild to very severe renal dysgenesis. Depending on the
level of Fgf9 and Fgf20, the mutant kidneys exhibited
reduced numbers of Six2-positive progenitor cells and also
more mature nephrons distal to the ureteric tips. When the
metanephric mesenchyme was grown as explant culture in
serum free media, addition of Fgf9 or Fgf20 was sufficient
to promote survival and proliferation of some progenitor
cells. These findings indicate that Fgf9 and Fgf20 act
redundantly to maintain the nephrogenic zone. Reduction
in the level of these growth factors leads to premature
differentiation of the progenitor cells within the niche.
Thus, the function of Fgf9 and Fgf20 is to maintain self-
renewal of renal progenitors in the condensed metanephric
mesenchyme.
Fgfrs in early kidney development
All Fgfrs are expressed in the developing rat kidney as
demonstrated by RT-PCR and by in situ hybridization [27].
Fgfr1 was found to be widely distributed in the meta-
nephric mesenchyme and epithelia, Fgfr2 in the ureteric
bud and in nephron epithelia, Fgfr3 in mesenchymal con-
densates, nephron elements and medullary interstitium and
Fgfr4 mainly in maturing nephrons. Knockout mice were
generated to study the function of these receptors in early
development (Table 1). Mice with a targeted disruption of
the Fgfr1 gene died between embryonic day E7.5 and E9.5
[47, 48] well before the metanephric kidneys started to
develop. Similarly, knockout of Fgfr2 (both isoforms
Fgfr2b and Fgfr2c) resulted in embryonic lethality after
implantation of the embryo in the uterus [49, 50]. Knock-
out mice with a targeted deletion of only the Fgfr2b
isoform died at birth due to lung agenesis [51]. These
animals lacked all limbs and had smaller kidneys, remi-
niscent of the Fgf10 knockout mice described above [40],
indicating that Fgf10 is the major ligand for Fgfr2b.
Transgenic mice, which overexpressed the extracellular
domain of Fgfr2b in soluble form, displayed severe kidney
dysgenesis in addition to multiple abnormalities of the
lung, skull, limbs, skin and eyes [52]. The soluble protein
appeared to act as a dominant negative receptor for Fgf
ligands, sequestering ligands away from the endogenous
receptors. Mice with targeted disruptions of Fgfr3 [53],
Fgfr4 [54] or compound disruption of Fgfr3 and Fgfr4 [54]
did not reveal any overt kidney phenotype. It is therefore
unlikely that these receptors play a major role during early
kidney development.
To overcome the problem of embryonic lethality of
Fgfr1 and Fgfr2 knockout mice, one research group used a
conditional targeting approach and studied the phenotypes
of animals harboring conditional deletions of the two
receptors either in the ureteric bud or the metanephric
mesenchyme [55]. The authors used the Hoxb7 promoter to
drive expression of Cre recombinase specifically in the
ureteric bud of their mice [56]. These mice were crossed
with animals carrying lox-p sites flanking critical exons of
the Fgfr1 and Fgfr2 genes. Fgfr1 is expressed at low levels
in the ureteric bud and consequently, the Fgfr1UB-/- ani-
mals did not reveal any overt renal abnormalities. In
contrast, absence of Fgfr2 from the ureteric bud resulted in
Fgfr2UB-/- mice with abnormalities in ureteric bud
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branching. These mice exhibited thinner ureteric bud stalks
and fewer ureteric bud tips than control animals. The
ureteric tips revealed regions of reduced proliferation and
inappropriate apoptosis. Hybridization with a probe for
Foxd1 demonstrated abnormal thickening of the stroma in
the cortical region. However, the animals developed nor-
mal nephrons and were vital, although their kidneys
displayed an abnormal shape and contained fewer
glomeruli.
Since many effects of Fgfr signaling are mediated by the
intracellular docking protein Frs2a, the authors also studied
the influence of this protein [57]. Utilizing the same
strategy as described above, they deleted a critical region
of the Frs2a gene specifically in the ureteric bud. Kidneys
from Frs2aUB-/- animals were found to be smaller than
those from control animals but the reduction in size was
less pronounced than that of the Fgfr2UB-/- mice. To
further clarify the relationship between Fgfr2 and Frs2a,
they generated mice with two point mutations in Fgfr2 in
the binding site for Frs2a (L424A and R426A). These point
mutations are known to efficiently block the ability of
Frs2a to bind to Fgfr2 [58]. Unexpectedly, the Fgfr2LR/LR
mice did not show any abnormalities in ureteric branching
or in kidney size. This result suggests that Fgfr2 signals in
the ureteric epithelium via other adapter molecules than
Frs2a. Finally, the researchers generated mice with com-
pound deletions of Fgfr2 and Frs2a [59]. They found that
Fgfr2UB-/-;Frs2aUB-/- kidneys were more severely
affected than either Fgfr2UB-/- kidneys or Frs2aUB-/-
kidneys. Together with the observation gained with the
point mutations, these results suggest that Fgfr2 and Frs2a
act separately and additively during branching morpho-
genesis of the kidney. One possibility is that Frs2a is used
primarily by the tyrosine kinase Ret, and not by Fgfr2, for
signaling in the ureteric bud. Fgfr2 in turn might utilize
another adaptor protein (such as PLCc) for downstream
signaling in the ureteric epithelium.
The same research group also analyzed the roles of
Fgfr1 and Fgfr2 in the metanephric mesenchyme (Table 1).
The Pax3 promoter was used to drive expression of Cre
recombinase specifically in the metanephric mesenchyme
[60]. The Cre mice were crossed as above with animals
carrying lox-p sites flanking critical exons of the Fgfr1 and
Fgfr2 genes. Although Fgfr1 and Fgfr2 are both expressed
in the metanephric mesenchyme (Fig. 3), Fgfr1MM-/- and
Fgfr2MM-/- mice developed normal kidneys. Occasion-
ally, the Fgfr2MM-/- mice had two ureteric buds,
suggesting that Fgfr2 is critical for ensuring that a single
ureteric bud is formed from the Wolffian duct. Thus, Fgfr2
appears to be involved in the regulation of the ureteric bud
induction site [61]. When the researchers deleted both
Fgfr1 and Fgfr2 in the metanephric mesenchyme, they
observed complete renal aplasia [60]. At E10.5 the
compound null mice showed no condensed metanephric
mesenchyme, but invasion of the ureteric bud into the
mesenchyme occurred normally. At E11.5 the mutant mice
had ureteric buds that failed to elongate and to branch. The
metanephric mesenchyme still expressed the marker genes
Eya1 and Six1, but there was no expression of the down-
stream genes Six2, Sall1 and Pax2. It is therefore likely that
Fgfr1 and Fgfr2 act downstream of Eya1 and Six1 in the
metanephric mesenchyme, but upstream of Six2, Sall1 and
Pax2. The mesenchyme showed abnormally high rates of
apoptosis and relatively low proliferation in regions that
would usually develop into condensed metanephric mes-
enchyme. Together, Fgfr1 and Fgfr2 are therefore required
for normal formation of the metanephric mesenchyme but
some redundancy exists and each receptor can substitute
for the other.
The researchers also studied the roles of the two splice
variants Fgfr2b and Fgfr2c in renal development [62]. They
found that Fgfr2b was mainly expressed in the epithelium
of the Wolffian duct and ureteric tree, but to some extent
also in the cap mesenchyme. Deletion of Fgfr2c did not
affect kidney development. However, deletion of Fgfr2c
together with conditional deletion of Fgfr1 in the meta-
nephric mesenchyme led to renal dysgenesis. The
phenotype was somewhat milder than that of the mice with
compound deletion of Fgfr1MM-/- and Fgfr2MM-/- (see
above). In particular, some metanephric mesenchyme that
expressed Six2 and Pax2 was identified at early stages, but
the Fgfr1MM-/-;Fgfr2c-/- mice had no renal tissue beyond
E12.5. Thus, Fgfr1 and Fgfr2c act redundantly and at least
one of the two receptors is required in the metanephric
mesenchyme for normal kidney development.
Role of FgfrL1 in early kidney development
To investigate the function of the fifth receptor, our group
has generated mice with a targeted disruption of the FgfrL1
gene. The promoter region and the first two exons of this
gene were replaced by a neo cassette [63]. FgfrL1 is nor-
mally expressed in all nephrogenic structures of the cortical
zone, including pretubular aggregates, renal vesicles,
comma- and S-shaped bodies [64, 65] (Fig. 3). It is also
found in tubules of the nascent nephrons and in the ureteric
bud epithelium, but it is not expressed in the cortical and
medullary stroma or in fully differentiated glomeruli.
Staining of an E15.5 kidney by whole mount in situ
hybridization is shown in Fig. 4. FgfrL1 knockout mice
were born alive but died immediately after birth due to
respiratory problems. These problems were explained by a
rudimentary diaphragm muscle that was not strong enough
to inflate the lungs after birth. However, the major alter-
ation of our knockout mice was the nearly complete
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absence of the metanephric kidneys [64]. The FgfrL1 null
mice contained only a small nodule at the end of the ureter
that was barely thicker than the ureter itself.
At E11.5, the ureter had begun to invade the metanephric
mesenchyme of the mutant kidneys and to branch. At E12.5,
the mesenchyme had condensed around the ureteric tips to
form the cap mesenchyme but then the condensed mesen-
chyme did not undergo the mesenchymal-to-epithelial
transition. Consequently, no epithelial renal vesicles formed
and the ureteric tips ceased to branch. At E14.5 increased
apoptosis was observed in the cortical zone of the devel-
oping kidney and reduced proliferation was noted in the
metanephric mesenchyme. The expression of marker genes
was investigated by RT-PCR, by in situ hybridization and by
immunohistochemistry [64]. Expression of the nephrogenic
markers Wnt4, Lhx1 and Fgf8 was significantly reduced.
However, markers of the uninduced mesenchyme (Six2,
Eya1, Wt1) or markers of the ureteric bud (Wnt9b, Wnt11)
were barely affected. Organ cultures performed with kidney
rudiments dissected from mutant mice at E11.5 confirmed
these observations [64]. The cultures showed no differenti-
ation of the mesenchyme and severely reduced branching of
the ureter. Taken together, our in vivo and in vitro studies
suggest that the ureteric bud of FgfrL1 deficient animals
received the correct signals to invade the metanephric
mesenchyme, where it branched several times and sent out
inductive signals to the mesenchyme. However, the meta-
nephric mesenchyme was not responsive to these signals and
failed to differentiate into epithelial structures. As a conse-
quence, branching of the ureteric tips stopped and the
uninduced cells started to decay by apoptosis.
To identify genes that may act downstream of FgfrL1 in
the regulatory hierarchy of genes required for early neph-
ron development, we used DNA microarray profiling [65].
When the gene expression profiles of kidney rudiments
from wild-type and knockout mice were compared at
E12.5, we detected 56 differentially expressed transcripts
with 2-fold or greater reduction in the mutant kidneys,
including Fgf8, Wnt4 and Lhx1. The best hits with the
most significant changes in expression levels are listed in
Table 2. Most of these hits are normally expressed in the
renal vesicles and/or the ureteric bud as indicated by the
gene expression data provided by GUDMAP [66]. An
interesting finding of our microarray experiments was that
the lack of FgfrL1 expression was barely compensated for
by the up-regulation of other genes. In particular, the
classical receptors Fgfr1–Fgfr4 did not show any altered
expression in the mutant kidneys. The fact that no signature
of increased Fgf signaling could be detected raises the
intriguing possibility that FgfrL1 might also be involved in
pathways or activities other than Fgf signaling.
Mechanism of FgfrL1 action
The molecular mechanisms, by which FgfrL1 controls
nephron formation, are not yet clear. Together with Wnt4,
FgfrL1 is one of the unique genes whose deletion specifi-
cally interferes with kidney formation, without grossly
affecting other organs of the animal. We have reported that
FgfrL1 knockout mice have a hypoplastic diaphragm
muscle but that all other muscles appear to be normal [63].
We also observed subtle alterations in the skeleton, in
particular in the skull [19]. Another group of researchers,
who generated FgfrL1 deficient mice by deletion of exons
3–7, described hypoplasia of several skeletal elements
(shortened bones, malformed vertebrae), heart defects
(thickened ventricular valves, septation anomalies) and
transient fetal anemia in mutant mice, but they did not
report any data about the missing kidneys [67]. We have
evidence that most of these relatively mild alterations are
secondary effects due to the absence of the kidneys.
Bilateral kidney agenesis causes oligohydramnios, a defi-
ciency of amniotic fluid, also termed Potter sequence or
FgfrL1 Calb1
Fig. 4 Expression pattern of FgfrL1 in mouse kidneys. Distribution
of the FgfrL1 mRNA is shown at E15.5 by whole mount in situ
hybridization with a probe for mouse FgfrL1 (left) and mouse
calbindin (control, right). Expression of FgfrL1 is widely observed in
the nephrogenic zone of the developing kidney but barely in the
adrenal gland or the gonads. Expression of calbindin is restricted to
the ureteric buds. See [64, 65] for details on the experimental
procedures
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Potter syndrome [68]. Furthermore, the lack of the kidneys
will affect the renin–angiotensin system of the growing
fetus because renin is produced in the arterioles of the
kidneys [69]. When renin is absent from the blood circu-
lation, angiotensinogen cannot be converted to angiotensin
and the fetus will be subjected to a life-threatening hypo-
tension. Together with the deficiency of the amniotic fluid,
this hypotension will cause a dramatic compression of the
embryo. In fact, human fetuses with Potter syndrome show
typical signs of intrauterine compression, such as facial
dysmorphia, lung hypoplasia and skull ossification defects
with large sutures [68]. Skull ossification defects are a
common consequence of the low blood pressure since
nascent bones need a high oxygen tension for normal
growth. Oligohydramnios and hypotension are also
observed in mice lacking the metanephric kidneys [69, 70].
Most of the alterations in the skeleton of our knockout mice
can therefore be explained by the missing kidneys. Our
conclusion is further supported by findings from a third
group of researchers who developed FgfrL1 deficient mice
and published the results as a patent application [71]. These
authors reported that all their homozygous FgfrL1-/- mice
died around birth and exhibited a fully penetrant kidney
phenotype with bilateral kidney dysgenesis/agenesis as
observed with our mice. At embryonic stage E10.5, the
ureteric bud of their FgfrL1 deficient mice still invaded the
metanephric mesenchyme, but then failed to branch and
form the characteristic T-shaped structure. Expression of
Pax2 was severely reduced in the metanephric mesen-
chyme as in our mice. It is therefore likely that kidney
dysgenesis/agenesis is a general feature of FgfrL1 knock-
out mice.
The FgfrL1 gene occurs in most animal classes, from
sea anemones to fish and mammals [15, 16]. In contrast,
metanephric kidneys are only found in amniotes, that is
reptiles, birds and mammals. Fish and amphibians have
pronephros and mesonephros but no metanephric kidneys.
Therefore FgfrL1 must have taken over a completely novel
function during the evolution of higher vertebrates. Inter-
estingly, pronephros and mesonephros, which also develop
in mammals, do not appear to be affected in our knockout
animals [64]. Curiously enough, FgfrL1 expression is rel-
atively low in the developing kidneys, while it is relatively
high in the skeleton, especially in cartilage [14]. To our
surprise, cartilaginous elements did not appear to be
affected in our FgfrL1 deficient mice.
The kidney alterations observed in FgfrL1 deficient
mice appear to be highly similar to the phenotypes of mice
that harbor specific deletions of Fgf8, Wnt4 or Lhx1.
Animals with a conditional deletion of Fgf8 in the meta-
nephric mesenchyme initiate nephrogenesis, but nephron
development is arrested at the stage of the renal vesicle [5,
6]. Mice with a global deletion of Wnt4 fail to form renal
vesicles, however other aspects of mesenchymal and ure-
teric development are barely affected [7]. Mice with a
conditional deletion of Lhx1 have kidneys with renal ves-
icles that do not develop beyond the S-shaped body stage
[74]. Nascent nephrons from kidneys that lack Wnt4 or
Lhx1 still express Fgf8 [5, 6]. In our FgfrL1 null mice,
nephron development appears to be affected at an earlier
stage because the condensed mesenchyme fails to undergo
the mesenchymal-to-epithelial transition and because no
renal vesicles can be observed [64]. Kidney development is
blocked even at an earlier stage in mice with a compound
Table 2 Differential gene expression between wild-type and FgfrL1 deficient kidneys at E12.5
Gene name Fold change wt/ko Protein accession Amino acids Subcellular localization Function Location of expression
Array qPCR
Svopl 9.5 9.4 Q6PDF3 494 Membrane Transporter RV
Krt23 7.4 17.4 Q99PS0 422 Cytoskeleton Intermediate filament UB
Slc32a1 7.0 [20 O35633 525 Membrane Transporter UB, RV
Wnt4 6.2 13.3 P22724 351 Secreted Growth factor RV
Dkk1 5.4 3.0 O54908 272 Secreted Antagonist of Wnt UB, RV
Egr1 4.9 4.6 P08046 533 Nucleus Transcription factor UB, mesenchyme
Pcp4 4.4 17.0 P63054 62 Cytosol Neuronal differentiation Bladder
Fgf8 4.4 9.2 P37237 268 Secreted Growth factor RV
Lhx1 4.1 7.7 P63006 406 Nucleus Transcription factor UB, RV
Sp5 3.7 Not done Q9JHX2 398 Nucleus Transcription factor RV
Aldh1a1 3.5 4.0 P24549 501 Cytosol Redox enzyme Ovary, testis
Clec18a 3.4 2.3 Q7TSQ1 534 Secreted C-type lectin RV
FgfrL1 3.1 6.8 Q91V87 529 Membrane Growth factor receptor UB, RV
RV renal vesicle, UB ureteric bud
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deletion of the receptors Fgfr1 and Fgfr2 that lack a proper
metanephric mesenchyme [60]. Although a linear hierarchy
of genes might be too simplistic and will have to be taken with
a lot of precaution, we can tentatively draw a cascade of genes
required for early nephron development in the metanephric
mesenchyme as follows: Fgfr1/Fgfr2 [ FgfrL1 [ Fgf8
[ Wnt4, Lhx1. This order is consistent with the fact that
expression of Fgf8, Wnt4 and Lhx1 is missing in our FgfrL1
deficient mice.
It is worthwhile to mention in this context that Fgf
signaling often acts in concert with Wnt signaling to evoke
a complete response [72]. Fgf8 for example is required to
initiate Wnt4 expression in pretubular aggregates of the
metanephric mesenchyme and, in turn, Wnt4 signaling
reinforces Fgf8 expression in nascent renal vesicles [5, 6].
Generally, it appears that the two pathways have opposing
effects on the transcription of co-regulated genes, at least in
the zebrafish tailbud [73]. During development of the
mouse kidney, Wnt9b is secreted from the ureteric bud into
the metanephric mesenchyme, where it triggers the
canonical b-catenin pathway and initiates nephron forma-
tion [4]. However, the corresponding Fgf pathway has not
yet been described. Given the strikingly similar phenotypes
of Wnt9b deficient kidneys and FgfrL1 deficient kidneys
and the fact that Wnt9b is still expressed in the FgfrL1
deficient epithelium, it is tempting to speculate that FgfrL1
represents the mediator of the Fgf signal that acts in concert
with Wnt9b to initiate nephron formation.
Currently, we envisage two possible molecular mecha-
nisms how FgfrL1 might be involved in nephron formation.
We have demonstrated that FgfrL1 binds Fgf ligands and that
it can act as a decoy receptor, especially when it is shed from
the plasma membrane [20]. It could therefore sequester Fgfs
away from the signaling receptors Fgfr1/Fgfr2. Of all Fgfs
that are expressed in the metanephric mesenchyme (Fgf1, 7,
8, 9, 10, 12, 20) only Fgf8 appears to bind to FgfrL1 with high
affinity, whereas Fgf1, 7, 9, 12 and 20 do not interact at all
[20]. Fgf8 might therefore represent the major ligand for
FgfrL1 in the kidney. This notion is consistent with the
observation that FgfrL1 is usually expressed in tissues that
also express Fgf8. In fact, the two proteins have been reported
to form a synexpression group in Xenopus laevis [75]. If
FgfrL1 binds Fgf8 it may control the diffusion range of this
morphogen and restrict it to the location where the renal
vesicle has to form. Indeed, Fgf8 has been found to act as an
important tissue organizer in other organs. During develop-
ment of the eye, Fgf8 is part of the ‘‘FGF signaling center’’
that triggers differentiation of retinal ganglion cells [76].
During formation of the encephalon, Fgf8 is involved in the
establishment of the isthmic organizer that controls devel-
opment of the midbrain and hindbrain [77].
It is of interest to note in this context that the homolo-
gous receptor FgfrL1 from the flat worm Dugesia japonica,
which was termed nou-darake (‘‘brains everywhere’’),
might function in a similar way [78]. Nou-darake is spe-
cifically expressed in the head region of the flat worms.
Depletion of the receptor by RNAi resulted in formation of
ectopic brain tissue throughout the body of the animals.
These results suggest that nou-darake might bind and
neutralize a brain-inducing factor (probably an Fgf) and
restrict the diffusion radius of this factor to the planarian
head. It is conceivable that FgfrL1 acts in a similar way in
the developing mouse kidney. FgfrL1 is expressed at rel-
atively low levels in the renal vesicle. It might therefore be
able to neutralize Fgf8 only in regions where the levels of
this morphogen are low, that is in the distal region of the
secreting source (Fig. 5). In the proximal regions where the
Fgf8 levels are high and exceed the levels of FgfrL1, Fgf8
cannot be neutralized and consequently, signaling via its
receptors Fgfr1/Fgfr2 may take place despite the presence
of FgfrL1. In this way, FgfrL1 would confine Fgf signaling
to the precise location of the renal vesicle (Fig. 5).
A second possibility would be that FgfrL1 acts as a
major cell adhesion protein. We have demonstrated that it
efficiently promotes fusion of CHO cells in vitro [23]. To
our knowledge, there is no evidence for any cell–cell
fusion event occurring during nephron development.
However, cell fusion might just be the most extreme result
of very tight cell adhesion that in the case of CHO cells
might end up in membrane fusion. Under normal condi-
tions, FgfrL1 might only bring together the cell membranes
into intimate contact. In fact, FgfrL1 is able to induce tight
adhesion of various cell types if coated on plastic plates
[22]. Furthermore, FgfrL1 is found at the contact sites of
cells in the renal vesicles [64, 65]. The receptor could
therefore function, together with other cell adhesion pro-
teins, in the condensation of the metanephric mesenchyme
around the ureteric tips. If FgfrL1 is absent as observed in
our knockout mice, the other adhesion molecules might not
Signaling Range
Level of FgfrL1
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Fig. 5 Restriction of Fgf8/Fgfr1 signaling to nephrogenic structures
by FgfrL1. FgfrL1, which is widely expressed in the nephrogenic
zone of the developing kidney, binds and neutralizes Fgf8, which is
secreted by nascent nephrons. If the concentration of FgfrL1 is lower
than that of Fgfr1 and if the affinity of FgfrL1/Fgf8 is higher than that
of Fgfr1/Fgf8, FgfrL1 could neutralize Fgf8 in regions that have low
levels of Fgf8, but not in regions that have high levels. FgfrL1 would
therefore restrict the signaling range of Fgf8 to the region of the
secreting source, the renal vesicle
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be able to bring together the mesenchymal cells into close
contact and the mesenchymal-to-epithelial conversion
might then not take place.
Further studies will be required to discriminate between
the two possibilities outlined above. It is also conceivable
that the two possibilities are not mutually exclusive and
that FgfrL1 acts as a modulator to restrict the Fgf8 diffu-
sion range as well as an adhesion protein to properly align
mesenchymal cells for epithelial conversion.
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